Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

Share Price is delayed by 15 minutes
Get Live Data
41.50    0.00 (0.00%)
Bid:
41.00
Ask:
41.80
Spread: 0.80 (1.951%)
Market Cap: £30.06m
NCYT Live PriceLast checked at - London Stock Exchange

Intraday Novacyt Share Chart

AGM Voting

13 Jun 2022 07:00

RNS Number : 5630O
Novacyt S.A.
13 June 2022
 

 

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

AGM voting

 

Paris, France and Camberley, UK - 13 June 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as an open online meeting at 2pm CEST/1pm BST on 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

 

Under French law, for the meetings to be quorate at the first attempt, at least 20% of the shareholders must vote on the ordinary resolutions and 25% of the shareholders must vote on the extraordinary resolutions. Shareholders are therefore strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the notice convening the meeting, copies of which are available in the General Meetings section on the Company's website at www.novacyt.com/investors.

 

Following registration and proof of shareholding, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors. Shareholders who have already voted (through a proxy, using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able to vote twice.

 

- End -

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com  

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com  

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKBBBDBKBKAD
Date   Source Headline
11th Sep 20237:55 amRNSCancellation of trading of Yourgene Shares
8th Sep 202312:00 pmRNSCompletion of acquisition of Yourgene Health plc
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Sep 202312:22 pmRNSCourt sanction of the Scheme of Arrangement
1st Sep 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Aug 20237:00 amRNSNotice of rescheduled AGM
17th Aug 20235:16 pmRNSAcquisition update
1st Aug 202311:45 amRNSLiquidity Agreement and Total Voting Rights
27th Jul 20237:00 amRNSHalf Year Trading Update
19th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
18th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
17th Jul 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
13th Jul 20237:00 amRNSNotice of cancelled AGM
12th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
3rd Jul 202312:00 pmRNSLiquidity Agreement and Total Voting Rights
3rd Jul 20237:01 amRNSRecommended cash offer for Yourgene Health plc
15th Jun 20234:00 pmRNSNotice of rescheduled AGM
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.